When is Vorasidenib expected to be launched in China?

Vorasidenib (Vorasidenib) is an innovative small molecule targeted drug specifically designed for patients with low-grade gliomas with IDH1 and IDH2 gene mutations. This type of drug prevents abnormal metabolism of tumor cells and slows down tumor growth by inhibiting the activity of IDH mutant enzyme. Vorsidenib was approved by the US FDA in 2024, becoming the world's first approved IDH1/2 dual inhibitor, bringing new treatment hope to patients with related cancers. In addition, it has also been approved for use in Canada, Australia, Israel and other countries, and its recognition in the international market continues to increase.

In China, vorsidenib has not yet completed the formal approval process by the National Food and Drug Administration (NMPA) and has not yet entered the nationwide market. However, relying on the special policy of the Hainan Boao Lecheng International Medical Tourism Pilot Zone, Voxirinib is listed as a "clinically urgently needed imported drug", allowing some patients to obtain drug treatment under strict supervision and approval, which provides a feasible path for clinical use. At the same time, a number of China's top medical institutions have carried out clinical bridging studies on vorsidenib, with the purpose of verifying the safety and effectiveness of the drug in Chinese patients and promoting its official marketing approval as soon as possible.

Clinical trials of vorsidenib in China are actively advancing. For example, Beijing Tiantan Hospital, as an important center for clinical trials, has completed the screening of the first patient and is further carrying out related research work. This type of bridging research not only helps speed up the drug approval process, but also promotes the integration of China with international treatment standards, improving the treatment level and choice of local patients. With the accumulation of trial data and the increase in review speed, the possibility of Voxanib being launched in China continues to increase.

In general, although voroxiranib has not yet been officially launched in China, with the special policy support of Hainan Boao Lecheng Pilot Zone and the promotion of active clinical trials in China, the drug is expected to enter the Chinese market in the next few years and become an important treatment option for patients with low-grade glioma and other IDH mutation-related diseases. Patients and doctors should also pay attention to relevant policies and clinical trial progress, seize early use opportunities, and bring good news to more patients.

Reference materials:https://www.drugs.com/seladelpar.html